Fresenius | FRE - Cash And Equivalent


Fresenius reported EUR1.28B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Akzo Nobel EUR 3.19B 430M Jun/2026
Alcon AG USD 1.36B 223M Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
BASF EUR 4.05B 3.74B Sep/2026
Bayer EUR 4.29B 1.44B Jun/2026
Beiersdorf EUR 1.28B 82M Jun/2026
DaVita Healthcare Partners USD 495.63M 173.33M Sep/2026
Demant DKK 1.5B 166M Jun/2026
E.ON EUR 3.44B 257M Sep/2026
Essilor EUR 1.93B 1.61B Jun/2026
Fresenius EUR 1.28B 780M Jun/2026
Fresenius Medical Care EUR 1.1B 37.86M Sep/2026
Getinge SEK 2.05B 909M Jun/2026
Givaudan CHF 603M 3M Jun/2024
GlaxoSmithKline GBP 3.1B 337M Jun/2026
GN Store Nord DKK 685M 121M Sep/2026
GRIFOLS EUR 486M 27M Sep/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Lonza CHF 719M 188M Dec/2025
Merck EUR 1.96B 788M Jun/2026
Novartis USD 8.87B 1.25B Sep/2026
Philips EUR 2.75B 962M Sep/2026
Roche Holding CHF 7.55B 579M Jun/2025
RWE EUR 4.5B 2.36B Sep/2026
Sanofi EUR 6.35B 806M Jun/2026